Mineralys Therapeutics, Inc. (MLYS) files 8-K
Filed: 2026-10-29 AccNo: 0001933414-26-000136 Size: 149 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement
MINERALYS THERAPEUTI (MLYS) is down -14.41% in the latest session. Our newswire has captured 2 stories on MLYS across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
The written analysis for MLYS publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
Filed: 2026-10-29 AccNo: 0001933414-26-000136 Size: 149 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement
RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid...
MINERALYS THERAPEUTI (MLYS) is down -14.41% in the latest session. Our newswire has captured 2 stories on MLYS across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "Mineralys Therapeutics, Inc. (MLYS) files 8-K" (SEC 8-K).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of MLYS coverage reads 50/100 over 2 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on MLYS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.